News & Comment

The nanotechnology-enabled mRNA-based vaccine platform recently approved against COVID-19 bears hope for improved vaccine development and trialling capacities in low- and middle-income countries as part of a broader global public health agenda.

To achieve the biggest impact, nanotechnology-based strategies developed to manage infectious diseases in resourced-limited settings need to take into account the local context.

Sharing protocols with the end-users may allow their flexible implementation to produce nanotechnology solutions for global health challenges that better cater for local needs.

When developing nanotechnology solutions for global health it is important to be mindful of the ethical, environmental, socio-economical, cultural and legal aspects associated with their deployment.

We have launched a series of webinars to engage our audience in a way that is complementary to the publication of articles.

The understanding of catalytic nanomaterials and processes results in improved control over their performance to achieve commercial relevance.

Flexibly designed nanomaterials can trigger specific immune responses and might offer promising alternatives to traditional immunosuppressive therapies, cancer immunotherapies and vaccine formulations.